By geography, Cytek’s U.S. revenue rose 32% year-over-year to $24.4 million. Jiang said performance in the U.S. was “broad-based” and included sales to academic institutions and biopharma companies, with a high percentage of buyers having purchased at least one instrument in the prior four quarters. EMEA revenue fell 7% to $10.8 million, with Jiang attributing softer instrument revenue to disruption from the conflict in the Middle East and an end-of-quarter shipment delay in another region, partially offset ...